KR102469798B1 - 이톨리주맙의 cd6 에 대한 인산화 감소 용도 - Google Patents
이톨리주맙의 cd6 에 대한 인산화 감소 용도 Download PDFInfo
- Publication number
- KR102469798B1 KR102469798B1 KR1020197014350A KR20197014350A KR102469798B1 KR 102469798 B1 KR102469798 B1 KR 102469798B1 KR 1020197014350 A KR1020197014350 A KR 1020197014350A KR 20197014350 A KR20197014350 A KR 20197014350A KR 102469798 B1 KR102469798 B1 KR 102469798B1
- Authority
- KR
- South Korea
- Prior art keywords
- alcam
- ser
- receptor
- antibody
- itolizumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physical Education & Sports Medicine (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Electrically Operated Instructional Devices (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641035602 | 2016-10-18 | ||
| IN201641035602 | 2016-10-18 | ||
| PCT/IB2017/056403 WO2018073721A1 (en) | 2016-10-18 | 2017-10-16 | Use of itolizumab to reduce phosphorylation of cd6 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190070957A KR20190070957A (ko) | 2019-06-21 |
| KR102469798B1 true KR102469798B1 (ko) | 2022-11-22 |
Family
ID=62019244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020197014350A Active KR102469798B1 (ko) | 2016-10-18 | 2017-10-16 | 이톨리주맙의 cd6 에 대한 인산화 감소 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190248913A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3528846A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7065085B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR102469798B1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017345390B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3076861A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL266087B2 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018073721A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2993186T (pt) | 2008-03-14 | 2019-11-29 | Biocon Ltd | Anticorpo monoclonal e um método do mesmo |
| US10189899B2 (en) | 2013-07-23 | 2019-01-29 | Biocon Limited | Use of a CD6 binding partner and method based thereon |
| KR102514528B1 (ko) | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
| WO2019169015A1 (en) * | 2018-02-27 | 2019-09-06 | Equillium, Inc. | Anti cd6 antibodies for treating severe asthma |
| US20230076643A1 (en) * | 2019-12-30 | 2023-03-09 | City Of Hope | Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113083A1 (en) | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10189899B2 (en) * | 2013-07-23 | 2019-01-29 | Biocon Limited | Use of a CD6 binding partner and method based thereon |
| KR102514528B1 (ko) * | 2016-10-21 | 2023-03-27 | 바이오콘 리미티드 | 루푸스 치료를 위한 단일클론항체 및 이의 치료방법 |
| US20230151107A1 (en) * | 2020-04-04 | 2023-05-18 | Biocon Limited | Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 |
-
2017
- 2017-10-16 IL IL266087A patent/IL266087B2/en unknown
- 2017-10-16 EP EP17862860.8A patent/EP3528846A4/en active Pending
- 2017-10-16 CA CA3076861A patent/CA3076861A1/en active Pending
- 2017-10-16 AU AU2017345390A patent/AU2017345390B2/en active Active
- 2017-10-16 KR KR1020197014350A patent/KR102469798B1/ko active Active
- 2017-10-16 JP JP2019520731A patent/JP7065085B2/ja not_active Expired - Fee Related
- 2017-10-16 WO PCT/IB2017/056403 patent/WO2018073721A1/en not_active Ceased
-
2019
- 2019-04-17 US US16/387,442 patent/US20190248913A1/en not_active Abandoned
-
2023
- 2023-06-15 US US18/335,542 patent/US20240101700A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009113083A1 (en) | 2008-03-14 | 2009-09-17 | Biocon Limited | A monoclonal antibody and a method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190070957A (ko) | 2019-06-21 |
| EP3528846A1 (en) | 2019-08-28 |
| EP3528846A4 (en) | 2020-06-03 |
| US20190248913A1 (en) | 2019-08-15 |
| WO2018073721A1 (en) | 2018-04-26 |
| AU2017345390A1 (en) | 2019-05-02 |
| IL266087B1 (en) | 2023-10-01 |
| IL266087B2 (en) | 2024-02-01 |
| US20240101700A1 (en) | 2024-03-28 |
| JP2020504597A (ja) | 2020-02-13 |
| AU2017345390B2 (en) | 2024-08-08 |
| JP7065085B2 (ja) | 2022-05-11 |
| IL266087A (en) | 2019-06-30 |
| CA3076861A1 (en) | 2018-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11859000B2 (en) | Anti-CCR8 antibodies and uses thereof | |
| US11414490B2 (en) | Regulatory T cell mediator proteins and uses thereof | |
| US20240101700A1 (en) | Use of itolizumab to reduce phosphorylation of cd6 | |
| US11547741B2 (en) | Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies | |
| US20220227880A1 (en) | Monoclonal antibody and a method of use for the treatment of lupus | |
| US20230015969A1 (en) | Regulatory t cell mediator proteins and uses thereof | |
| JP2020527581A (ja) | 腫瘍微小環境における免疫応答を増強するための治療剤および方法 | |
| CN108431037A (zh) | 抗myl9抗体 | |
| KR20230015348A (ko) | Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물 | |
| US20220275070A1 (en) | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab | |
| CA3144921A1 (en) | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab | |
| RU2832188C2 (ru) | Дозировка и схема введения для лечения или предупреждения связанных с с5 заболеваний посредством применения антитела против с5 кровалимаба | |
| HK40070215A (en) | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab | |
| HK40065402A (en) | Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab | |
| HK40024980A (en) | Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 4 |